For the Inventor, By the Inventor

Enter assignee name

Danvers, MA, United States of America

Cell Signaling Technology, Inc.

USPTO Granted Patents = 59

CIPO Patents = 3

EPO Patents = 20

Trademarks = 28

Forward Citations = 245

Loading Chart...

Loading Chart...

52 inventors (with patents filed for the assignee):

Ailan Guo (28 out of 30 patents)

Ting-Lei Gu (21 out of 21 patents)

Herbert Haack (18 out of 18 patents)

4. Anthony Paul Possemato (17 out of 17 patents)

5. Klarisa Rikova (16 out of 26 patents)

6. Laura Sullivan (13 out of 13 patents)

7. Jian Yu (13 out of 19 patents)

8. Roberto Polakiewicz (13 out of 15 patents)

9. Michael Comb (12 out of 13 patents)

10. Joan MacNeill (12 out of 12 patents)

11. Albrecht Moritz (11 out of 12 patents)

12. John Edward Rush, Ii (9 out of 10 patents)

13. Katherine Eleanor Crosby (8 out of 8 patents)

14. Yi Tan (8 out of 9 patents)

15. Kimberly A Lee (7 out of 9 patents)

Core Competencies:

Mutant ROS Kinase

Anaplastic Lymphoma Kinase

Mass Spectrometry

Ubiquitinated Polypeptides

EGFR Detection

Monoclonal Antibodies

Non-Small Cell Lung Carcinoma

Protein Phosphorylation

Peptide Libraries

Immunoaffinity Isolation

Cancer Biomarkers

HER2-Directed Therapy

59 patents: Sort by Forward Citations

1. 11761005 - Translocation and mutant ROS kinase in human non-small cell lung carcinoma (2023-09-19),

2. 11505833 - Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer (2022-11-22),

3. 11428696 - Mass spectrometry analysis of mutant polypeptides in biological samples (2022-08-30),

4. 11377486 - Motif-specific and context-independent antibodies that specifically bind to a sumoylated lysine-containing residue (2022-07-05),

5. 11352418 - Analysis of ubiquitinated polypeptides (2022-06-07),

6. 11099188 - ROS kinase in lung cancer (2021-08-24),

7. 10955416 - Compositions for detecting mutant anaplastic lymphoma kinase in human lung cancer (2021-03-23),

8. 10889818 - Translocation and mutant ROS kinase in human non-small cell lung carcinoma (2021-01-12),

9. 10870892 - Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer (2020-12-22),

10. 10670606 - Mass spectrometry analysis of mutant polypeptides in biological samples (2020-06-02),

11. 10577640 - Multi component detection (2020-03-03),

12. 10551383 - Methods of detecting a polypeptide having anaplastic lymphoma kinase activity in kidney cancer (2020-02-04),

13. 10526661 - Translocation and mutant ROS kinase in human non-small cell lung carcinoma (2020-01-07),

14. 10036756 - Mass spectrometry analysis of mutant polypeptides in biological samples (2018-07-31),

15. 10000568 - Compositions and methods for detecting EGFR in cancer (2018-06-19),

Cell Signaling Technology, Inc. (CST) specializes in the development and production of high-quality antibodies, kits, and related reagents for life science research. With over 1,000 employees worldwide, CST is committed to advancing scientific research and discovery through innovation and excellence in biological reagents. Visit their website to explore their extensive product catalog and learn more about their groundbreaking solutions in cell signaling.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

59 Patents

#4 in Danvers, MA

#334 in Massachusetts

#5,867 in US

#11,833 in the World

Danvers, MA, United States of America

Cell Signaling Technology, Inc.

Forward Citations = 245

52 inventors:

Ailan Guo (28 out of 30 patents)

Ting-Lei Gu (21 out of 21 patents)

Herbert Haack (18 out of 18 patents)

4. Anthony Paul Possemato (17 out of 17 patents)

5. Klarisa Rikova (16 out of 26 patents)

Please report any incorrect information to support@idiyas.com

Loading…